Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Int Cancer Conf J ; 9(3): 112-115, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32582513

ABSTRACT

A 63-year-old man had advanced poorly differentiated gastric adenocarcinoma with para-aortic lymph node metastases. No HER2 expression was observed in four endoscopic biopsies from the primary tumor. Tumors shrunk after S-1 with cisplatin treatment, and he underwent simple gastrectomy due to stenosis. Interestingly, HER2 diffusely overexpressed in the resected surgical specimen. His disease was stable with trastuzumab-containing therapy for 6.4 months. This case may suggest a selection of HER2-positive cells that were insensitive to the chemotherapy, and further study is needed for the change of intratumoral HER2 heterogeneity after chemotherapy.

2.
BMC Cancer ; 18(1): 1142, 2018 Nov 20.
Article in English | MEDLINE | ID: mdl-30458812

ABSTRACT

BACKGROUND: Anal canal cancer occasionally accompanies extramammary Paget disease. Although most of them are squamous cell carcinoma, anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease has never been reported. CASE PRESENTATION: Here, we report a 76-year-old man presented with pruritus in the perianal area. Investigation revealed a fist-sized perianal erythema, diffuse liver tumors, and right inguinal lymph node swelling. Pathological examination of biopsies from the erythema suggested secondary extramammary Paget disease with positive cytokeratin-7 and -20 expressions and negative GCDFP-15 expression. The anal canal tumor was confirmed by digital examination and endoscopy. Biopsies from the anal canal tumor, swollen lymph node, and Paget lesion all showed poorly differentiated adenocarcinoma with neuroendocrine features expressing synaptophysin and chromogranin A. Serum CEA and NSE levels were high, 809.4 ng/ml and 85.8 ng/ml, respectively. After chemotherapy with modified FOLFOX6 for 2 months, the Paget lesion disappeared, and the primary anal canal tumor and liver metastases shrunk remarkably. Serum CEA and NSE levels decreased promptly to within normal ranges. CONCLUSIONS: This is a clinically significant case, as it reveals novel pathological features about anal canal cancer with secondary Paget disease and successfully treated with modified FOLFOX6. Careful pathological investigation and appropriate treatment choice are needed for this rare cancer.


Subject(s)
Adenocarcinoma/drug therapy , Anal Canal/drug effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Anus Neoplasms/drug therapy , Paget Disease, Extramammary/drug therapy , Adenocarcinoma/complications , Adenocarcinoma/pathology , Aged , Anal Canal/pathology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Anus Neoplasms/complications , Anus Neoplasms/pathology , Carcinoma, Neuroendocrine/complications , Carcinoma, Neuroendocrine/drug therapy , Carcinoma, Neuroendocrine/pathology , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Male , Organoplatinum Compounds/administration & dosage , Paget Disease, Extramammary/etiology , Paget Disease, Extramammary/pathology , Treatment Outcome
3.
Intern Med ; 56(8): 921-923, 2017.
Article in English | MEDLINE | ID: mdl-28420840

ABSTRACT

Nanoparticle albumin-bound (nab)-paclitaxel has shown promising activity in advanced gastric cancer treatment. We herein report a case of advanced gastric cancer involving long-term management with a single administration of nab-paclitaxel. A 71-year-old man diagnosed with advanced gastric cancer with malignant ascites was treated with nab-paclitaxel as a second-line chemotherapy. He refused treatment continuation because of various severe toxicities in the first treatment cycle; he was therefore followed-up without any further treatments. Despite this, no disease progression was observed over 9 months. After progression, he received dose-dense paclitaxel, but he did not respond to this treatment and eventually died.


Subject(s)
Albumins/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Paclitaxel/administration & dosage , Peritoneal Neoplasms/drug therapy , Stomach Neoplasms/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Delivery Systems/methods , Fatal Outcome , Humans , Male , Nanoparticles/administration & dosage , Stomach Neoplasms/pathology
4.
Opt Express ; 23(2): 1585-93, 2015 Jan 26.
Article in English | MEDLINE | ID: mdl-25835916

ABSTRACT

A fan-in/out polymer optical waveguide with 25-µm cores and 40-µm interchannel pitch is fabricated for a multimode multicore fiber using a microdispenser. We design a fan-in/out structure to which the Mosquito method is applicable since the Mosquito method is capable of drawing a circular graded-index core three-dimensionally. Then, we experimentally fabricate a 10-cm long fan-in/out polymer waveguide with seven cores, which is expected to connect a multicore fiber and a fiber ribbon. A minimum insertion loss of 5.26 dB at 850-nm wavelength for a 10-cm long fan-in/out waveguide is experimentally observed. Causes of variation in the insertion loss and interchannel pitch are discussed.

5.
Opt Express ; 22(7): 8426-37, 2014 Apr 07.
Article in English | MEDLINE | ID: mdl-24718216

ABSTRACT

We successfully fabricate polymer optical waveguides with graded-index (GI) circular cores whose diameter and interchannel pitch are accurately controlled using the Mosquito method: GI-core waveguides with 250-, 125- and 62.5-µm pitches are successfully obtained. The Mosquito method utilizing a microdispenser is a very simple technique for fabricating GI-circular-core polymer optical waveguides. The accurately controlled pitch is confirmed by a high connectivity with a commercially available multimode fiber (MMF) ribbon with a 125-µm pitch. Furthermore, by inserting the waveguide between two 12-channel MMF ribbons, we experimentally demonstrate 11.3 Gbps × 12 Ch. parallel signal transmission through a GI-core waveguide with a 125-µm pitch for the first time to the best of our knowledge.

SELECTION OF CITATIONS
SEARCH DETAIL